The ”Disruptive Dozen” – Harnessing Technology to Reduce Health Disparities: Twelve mostly likely to have significant impact on healthcare by end of 2021.
Reporter: Aviva Lev-Ari, PhD, RN
2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET
https://worldmedicalinnovation.org/2020-disruptive-dozen/
VIEW VIDEOS from the event
https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg
From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>
Date: Tuesday, May 12, 2020 at 6:48 AM
To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>
Subject: REGISTRANT RECAP | World Medical Innovation Forum
Dear World Forum Attendee,
On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators. As promised, we wanted to also share visual Forum session summaries. You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning
We hope you will join us for the 2021 Forum!
Thanks again, Chris
e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET
Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET
The ”Disruptive Dozen” results from interviews of one hundred Mass General Brigham senior Harvard faculty followed by a rigorous selection process to identify the twelve mostly likely to have significant impact on healthcare by end of 2021.
|
|
Thomas Sequist, MD Chief Patient Experience and Equity Officer, PHS; Professor of Medicine and Health Care Policy, Harvard Medical School |
2. Harnessing Technology to Reduce Health Disparities Health is determined not just by genes, diet, and exercise, but also by the environments where people live, learn, work, and play. New technologies are emerging to help reduce health disparities and improve health outcomes. |
|
Orhun Muratoglu, PhD Alan Gary Scholar, Director Harris Orthopaedics Lab, MGH; Professor, Harvard Medical School |
4. Solving the Problem of Infection in Total Joint Replacements Total joint replacement is an increasingly common procedure. For most patients, recovery is uneventful and lasts a few months, but some experience a much more complicated and painful journey due to infection in the artificial joint. Find out how researchers are harnessing technology to help address this problem.
|
|
Calum MacRae, MD, PhD Vice Chair for Scientific Innovation, Department of Medicine, BH; Associate Professor of Medicine, Harvard Medical School |
3. Digital Management of Chronic Disease Chronic diseases are a major challenge for patients and health care systems alike. In 2016, the U.S. spent over a trillion dollars caring for patients with heart disease, diabetes, cancer and other chronic conditions. Find out how technology could help improve care for these patients — and lower costs.
|
|
|
David Scadden, MD Director, Center for Regenerative Medicine, MGH; Co-Director, Harvard Stem Cell Institute; Gerald and Darlene Jordan Professor of Medicine, Harvard Medical School |
7. New Therapeutic Options for Sickle Cell Disease Millions of people worldwide suffer from sickle cell disease. While the cause of this debilitating blood disorder has been known for half a century, only two drugs are currently available to treat it. New developments are on the horizon that could help transform the management of a disease that has too often been overlooked. |
|
Patricia Musolino, MD, PhD Co-Director Pediatric Cerebrovascular Service, MGH; Assistant Professor, Harvard Medical School |
6. Gene Therapies Transform Treatment of Rare, Devastating Diseases The emergence of the first gene therapies for clinical use signaled a watershed moment in the history of medicine. This treatment modality will do ever more in the coming year for patients, especially those with rare genetic conditions. |
|
Joan Miller, MD Chief of Ophthalmology, MEE and MGH; Ophthalmologist-in-Chief, BH; David Glendenning Cogan Professor of Ophthalmology and Chair, Department of Ophthalmology, Harvard Medical School |
5. New Tools to Help Aging Eyes and Ears Like many parts of the body, the eyes and ears can deteriorate with age, making them vulnerable to disease and loss of sensory functions. Find out how new technologies and treatments could help patients and clinicians better protect these organs from age-related decline. |
Astrid Weins, MD, PhD Associate Pathologist, Brigham Health; Assistant Professor, Pathology, Harvard Medical School |
10. Making Cells Larger to See Them More Clearly Visualizing cells at high-resolution is a cornerstone of modern biology and medicine. For more than a century, as scientists yearned to observe biological structures with greater power and clarity, they built more advanced microscopes. Yet today, even those sophisticated tools have limits. See how researchers are developing a innovative new approach to cell visualization. |
|
Dennis Selkoe, MD Co-Director of the Ann Romney Center for Neurologic Diseases, Brigham Health; Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School |
9. First Disease-Modifying Therapy for Alzheimer’s Disease The world lacks a meaningful treatment for Alzheimer’s disease, a progressive, debilitating neurodegenerative condition that affects millions across the globe. But that could change later this year, when the FDA is expected to weigh in on a novel drug that targets clumps of protein in the brain known as amyloid plaques. If approved, the drug would mark the first disease-modifying therapy for Alzheimer’s disease. |
|
Leonardo Riella, MD, PhD Medical Director, Vascularized Composite Tissue Transplantation, Brigham Health; Associate Physician, Harvard Medical School |
8. Keeping Transplant Organs Fresher for Longer Over 120,000 people in this country are now waiting for an organ transplant. What if it were possible to increase the time that organs can be safely stored outside the body prior to transplantation? Scientists are working to drive innovation in this area in an effort to expand the pool of donor organs available for those who need them. |
|
Leave a Reply